BTG (LON:BTG) and the Society of Interventional Oncology said today that it expanded its immuno-oncology/interventional oncology research grant program.
The group launched a second round of funding, designed help evaluate minimally invasive, image-guided therapies that use the body’s own immune system to treat cancer.
Get the full story at our sister site, Drug Delivery Business News.
The post BTG helps fund immuno-oncology drug-device research programs appeared first on MassDevice.